Shots:
- The US FDA has approved Lifyorli (relacorilant) + nab-paclitaxel for the treatment of adults with epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1-3 prior systemic therapies, ≥1 of which included Avastin
- NDA was supported by P-III (ROSELLA) assessing Lifyorli + nab-paclitaxel vs nab-paclitaxel alone in the above-mentioned pts (n=381) with no need for biomarker selection
- Trial met its dual 1EP of improved PFS & OS, showing a 35% reduction in death risk (mOS: 16 vs 11.9mos.) & a 30% reduction in the risk of disease progression as assessed by BICR; data was published in The Lancet
Ref: Businesswire | Image: Corcept Therapeutics | Press Release
Related News: Corcept Therapeutics Reports P-III (ROSELLA) Trial Data on Relacorilant for Platinum-Resistant Ovarian Cancer (PROC)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
